Novartis will pay $1 billion upfront to acquire radiopharmaceutical startup Mariana Oncology, just eight months after the preclinical biotech company disclosed a $175 million Series B.
The move, which could include another $750 million in milestones, further solidifies the Swiss drug giant’s embrace of the red-hot field of radiopharmaceuticals. Novartis markets two such medicines, Lutathera and Pluvicto, and just earlier this week expanded its radiopharma discovery tie-up with PeptiDream.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.